Statistics

Total Visits

Views
Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)14

Select a period of time:

Number of views in the range

Views
Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)9

Views

Views
November 20231
December 20231
January 20241
February 20241
March 20240
April 20240
May 20245
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States9
 

Top cities views

Views
Chicago3
Ashburn2
Boardman2